Diagnostic and Dosimetry Features of [64Cu]CuCl2 in High-Grade Paediatric Infiltrative Gliomas

[1]  G. Reifenberger,et al.  The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. , 2021, Neuro-oncology.

[2]  L. Mancini,et al.  Imaging characteristics of H3 K27M histone-mutant diffuse midline glioma in teenagers and adults. , 2021, Quantitative imaging in medicine and surgery.

[3]  M. Severino,et al.  Correlation of multimodal 18F-DOPA PET and conventional MRI with treatment response and survival in children with diffuse intrinsic pontine gliomas , 2020, Theranostics.

[4]  M. Petris,et al.  Copper metabolism as a unique vulnerability in cancer. , 2020, Biochimica et biophysica acta. Molecular cell research.

[5]  S. Gambhir,et al.  ED SUM: Triple-negative breast cancer is inhibited by depleting mitochondrial copper in mice. , 2020, Nature Biotechnology.

[6]  A. Broniscer,et al.  Improving long-term survival in diffuse intrinsic pontine glioma , 2020, Expert review of neurotherapeutics.

[7]  C. Hawkins,et al.  MR Imaging features of Diffuse Intrinsic Pontine Glioma (DIPG) and Relationship to Overall Survival: Report from the International DIPG Registry. , 2020, Neuro-oncology.

[8]  I. Pollack,et al.  Response assessment in diffuse intrinsic pontine glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. , 2020, The Lancet. Oncology.

[9]  I. Harting,et al.  Outcomes of BRAF V600E Pediatric Gliomas Treated With Targeted BRAF Inhibition. , 2020, JCO precision oncology.

[10]  D. Roy,et al.  PTPmu-targeted nanoparticles label invasive pediatric and adult glioblastoma. , 2020, Nanomedicine : nanotechnology, biology, and medicine.

[11]  A. Samdani,et al.  Diffuse intrinsic pontine gliomas: Diagnostic approach and treatment strategies , 2019, Journal of Clinical Neuroscience.

[12]  M. Bernaudin,et al.  64Cu-ATSM/64Cu-Cl2 and their relationship to hypoxia in glioblastoma: a preclinical study , 2019, EJNMMI Research.

[13]  W. Rashed,et al.  Pediatric diffuse intrinsic pontine glioma: where do we stand? , 2019, Cancer and Metastasis Reviews.

[14]  R. Polishchuk,et al.  Activity and Trafficking of Copper-Transporting ATPases in Tumor Development and Defense against Platinum-Based Drugs , 2019, Cells.

[15]  A. Shilatifard,et al.  Radiosensitization by Histone H3 Demethylase Inhibition in Diffuse Intrinsic Pontine Glioma , 2019, Clinical Cancer Research.

[16]  M. Severino,et al.  Advanced MR imaging and 18F-DOPA PET characteristics of H3K27M-mutant and wild-type pediatric diffuse midline gliomas , 2019, European Journal of Nuclear Medicine and Molecular Imaging.

[17]  J. Daoud,et al.  Pediatric high grade gliomas: Clinico-pathological profile, therapeutic approaches and factors affecting overall survival. , 2019, Neuro-Chirurgie.

[18]  S. Furlan,et al.  Characterization of the immune microenvironment of diffuse intrinsic pontine glioma: implications for development of immunotherapy , 2018, Neuro-oncology.

[19]  Ian Law,et al.  Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0 , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[20]  A. Charil,et al.  In vivo [64Cu]CuCl2 PET imaging reveals activity of Dextran-Catechin on tumor copper homeostasis , 2018, Theranostics.

[21]  E. Neromyliotis,et al.  Paediatric gliomas: diagnosis, molecular biology and management. , 2018, Annals of translational medicine.

[22]  F. Paparo,et al.  64CuCl2 PET/CT in Prostate Cancer Relapse , 2018, The Journal of Nuclear Medicine.

[23]  F. Paparo,et al.  Biokinetic and dosimetric aspects of 64CuCl2 in human prostate cancer: possible theranostic implications , 2018, EJNMMI Research.

[24]  M. Severino,et al.  Grading and outcome prediction of pediatric diffuse astrocytic tumors with diffusion and arterial spin labeling perfusion MRI in comparison with 18F–DOPA PET , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[25]  P. Kingsley,et al.  Variegated Colors of Pediatric Glioblastoma Multiforme: What to Expect? , 2017, Rare tumors.

[26]  Deric M. Park,et al.  Hypoxia in the glioblastoma microenvironment: shaping the phenotype of cancer stem-like cells , 2017, Neuro-oncology.

[27]  B. Hoeben,et al.  Survival benefit for patients with diffuse intrinsic pontine glioma (DIPG) undergoing re-irradiation at first progression: A matched-cohort analysis on behalf of the SIOP-E-HGG/DIPG working group. , 2017, European journal of cancer.

[28]  A. Nanda,et al.  A systematic review of overall survival in pediatric primary glioblastoma multiforme of the spinal cord. , 2017, Journal of neurosurgery. Pediatrics.

[29]  A. Duatti,et al.  Imaging of Brain Tumors with Copper-64 Chloride: Early Experience and Results. , 2016, Cancer biotherapy & radiopharmaceuticals.

[30]  R. Lustig,et al.  Patterns of Failure for Pediatric Glioblastoma Multiforme Following Radiation Therapy , 2016, Pediatric blood & cancer.

[31]  K. Iczkowski,et al.  Copper Transporter-CTR1 Expression and Pathological Outcomes in Platinum-treated Muscle-invasive Bladder Cancer Patients. , 2016, Anticancer research.

[32]  F. Barkhof,et al.  Survival prediction model of children with diffuse intrinsic pontine glioma based on clinical and radiological criteria. , 2014, Neuro-oncology.

[33]  S. Knapp,et al.  Copper is required for oncogenic BRAF signaling and tumorigenesis , 2013, Nature.

[34]  S. Mittal,et al.  Tryptophan PET-defined gross tumor volume offers better coverage of initial progression than standard MRI-based planning in glioblastoma patients , 2014, Journal of Radiation Oncology.

[35]  D. Hanahan,et al.  Bioavailable copper modulates oxidative phosphorylation and growth of tumors , 2013, Proceedings of the National Academy of Sciences.

[36]  M. Chamberlain,et al.  Brainstem Glioma: A Review , 2013, Current Neurology and Neuroscience Reports.

[37]  P. Span,et al.  Hypofractionation vs conventional radiation therapy for newly diagnosed diffuse intrinsic pontine glioma: a matched-cohort analysis. , 2013, International journal of radiation oncology, biology, physics.

[38]  P. Cassette,et al.  Standardization, decay data measurements and evaluation of 64Cu. , 2012, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[39]  J. Fangusaro.  Pediatric High Grade Glioma: a Review and Update on Tumor Clinical Characteristics and Biology , 2012, Front. Oncol..

[40]  M. Ansari,et al.  Pediatric glioblastoma multiforme: A single-institution experience , 2012, Indian Journal of Medical and Paediatric Oncology.

[41]  Daniel J Brat,et al.  Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group. , 2011, Neuro-oncology.

[42]  D. Richardson,et al.  ATP7A is a novel target of retinoic acid receptor β2 in neuroblastoma cells , 2009, British Journal of Cancer.

[43]  A. Barrientos,et al.  Mitochondrial copper metabolism and delivery to cytochrome c oxidase , 2008, IUBMB life.

[44]  E. Huskisson,et al.  The Role of Vitamins and Minerals in Energy Metabolism and Well-Being , 2007, The Journal of international medical research.

[45]  J. Valentin.  The 2007 Recommendations of the International Commission on Radiological Protection. ICRP publication 103. , 2007, Annals of the ICRP.

[46]  P. Julyan,et al.  A comparison of PET imaging characteristics of various copper radioisotopes , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[47]  Michael G Stabin,et al.  OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[48]  J. Crapo,et al.  Radiation Protection in Medicine , 2002 .

[49]  B. Wessels,et al.  MIRD pamphlet no. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[50]  M J Welch,et al.  Efficient production of high specific activity 64Cu using a biomedical cyclotron. , 1997, Nuclear medicine and biology.

[51]  Icrp.  1990 Recommendations of the International Commission on Radiological Protection , 1991 .

[52]  S. Adelstein,et al.  Intracellular distribution and radiotoxicity of chromium-51 in mammalian cells: Auger-electron dosimetry. , 1985, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[53]  M. Welch,et al.  Lethality of Auger electrons from the decay of bromine-77 in the DNA of mammalian cells. , 1982, Radiation research.

[54]  Icrp.  Recommendations of the International Commission on Radiological Protection, ICRP Publication 26 , 1977 .

[55]  S. Adelstein,et al.  The radiotoxicity of iodine-125 in mammalian cells II. A comparative study on cell survival and cytogenetic responses to 125IUdR, 131TUdR, and 3HTdR. , 1976, Radiation research.

[56]  Ws Snyder,et al.  MIRD Pamphlet #11: S, Absorbed Dose per Unit Cumulated Activity for Selected Radionuclides and Organs , 1975 .

[57]  M Berman,et al.  A schema for absorbed-dose calculations for biologically-distributed radionuclides. , 1968, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.